Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer

被引:10
|
作者
Hanson, Erik D. [1 ,2 ]
Alzer, Mohamdod [1 ]
Carver, Jackson [1 ]
Stopforth, Cameron K. [1 ]
Lucas, Alexander R. [3 ,4 ]
Whang, Young E. [2 ,5 ]
Milowsky, Matthew, I [2 ,5 ]
Bartlett, David B. [6 ,7 ]
Harrison, Michael R. [6 ]
Bitting, Rhonda L. [3 ]
Deal, Allison M. [2 ]
Stoner, Lee [1 ]
Hackney, A. C. [1 ,8 ]
Battaglini, Claudio L. [1 ,2 ]
机构
[1] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27515 USA
[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA
[3] Wake Forest Baptist Comprehens Canc Ctr, Winston Salem, NC USA
[4] Virginia Commonwealth Univ, Dept Hlth Behav & Policy, Richmond, VA USA
[5] Univ N Carolina, Dept Med, Div Oncol, Chapel Hill, NC USA
[6] Duke Univ, Duke Canc Inst, Div Med Oncol, Durham, NC USA
[7] Univ Surrey, Fac Hlth & Med Sci, Sch Biosci & Med, Guildford, Surrey, England
[8] Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC USA
关键词
ANDROGEN-DEPRIVATION THERAPY; QUALITY-OF-LIFE; PHYSICAL FUNCTION; BODY-COMPOSITION; FUNCTIONAL ASSESSMENT; CLINICAL-TRIAL; STRENGTH; ENZALUTAMIDE; ABIRATERONE; PROGRAM;
D O I
10.1038/s41391-022-00523-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Home-based training increases accessibility to exercise and mitigates the side effects of hormone therapy for prostate cancer (PC). However, it is unknown if men with more advanced disease are willing to partake in such interventions. Purpose To determine the feasibility of a home-based exercise intervention in men with metastatic castration-resistant prostate cancer (mCRPC). Methods mCRPC patients on androgen receptor signaling inhibitors (ARSI) were prescribed a 12-week, home-based exercise intervention using resistance bands and walking. Feasibility was assessed using recruitment, retention, adherence, and outcome capture. Physiological changes and patient reported outcomes were assessed before and after the intervention. Results Of the 62 referrals, 47 were eligible with 22 men performing baseline testing (47% recruitment rate) and 16 completing the intervention (73% retention). Task completion was >86% for all physiological tests. Walking adherence was 80% and resistance training was 63%, the latter falling short of the study target (75%). Training increased thigh muscle cross-sectional area by 22%, time to exhaustion by 19% (both p < 0.05) and peak oxygen uptake by 6% (p = 0.057). Improvements in short physical performance battery scores and 400 m walk demonstrated moderate effect sizes that did not reach significance. Conclusions Home-based exercise is feasible during ARSI treatment for mCRPC. Greater endurance capacity and localized hypertrophy appear as the primary improvements following training. These preliminary findings suggest home-based training may increase exercise accessibility, with important lessons that will inform subsequent trials investigating the efficacy of home-based exercise interventions during mCRPC.
引用
收藏
页码:302 / 308
页数:7
相关论文
共 50 条
  • [1] Feasibility of home-based exercise training during adjuvant treatment for metastatic castrate-resistant prostate cancer patients treated with an androgen receptor pathway inhibitor (EXACT)
    Brown, Malcolm
    Murphy, Marie H.
    McAneney, Helen
    McBride, Ken
    Crawford, Ffiona
    Cole, Aidan
    O'Sullivan, Joe M.
    Jain, Suneil
    Prue, Gillian
    SUPPORTIVE CARE IN CANCER, 2023, 31 (07)
  • [2] Treatment of metastatic, castration-resistant prostate cancer
    von Amsberg, G.
    Merseburger, A. S.
    UROLOGE, 2020, 59 (06): : 673 - 679
  • [3] Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer
    Marshall, Catherine H.
    Tunacao, Jessa
    Danda, Varun
    Tsai, Hua-Ling
    Barber, John
    Gawande, Rakhee
    Weiss, Clifford R.
    Denmeade, Samuel R.
    Joshu, Corinne
    BJU INTERNATIONAL, 2021, 128 (03) : 366 - 373
  • [4] Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer
    Graff, Julie N.
    Gordon, Max J.
    Beer, Tomasz M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (05) : 749 - 754
  • [5] Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
    Rodriguez-Vida, Alejo
    Galazi, Myria
    Rudman, Sarah
    Chowdhury, Simon
    Sternberg, Cora N.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 3325 - 3339
  • [6] Biomarkers in Metastatic Castration-resistant Prostate Cancer
    Miller, K.
    AKTUELLE UROLOGIE, 2015, 46 (01) : 66 - 70
  • [7] Olaparib for Metastatic Castration-Resistant Prostate Cancer
    de Bono, J.
    Mateo, J.
    Fizazi, K.
    Saad, F.
    Shore, N.
    Sandhu, S.
    Chi, K. N.
    Sartor, O.
    Agarwal, N.
    Olmos, D.
    Thiery-Vuillemin, A.
    Twardowski, P.
    Mehra, N.
    Goessl, C.
    Kang, J.
    Burgents, J.
    Wu, W.
    Kohlmann, A.
    Adelman, C. A.
    Hussain, M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (22): : 2091 - 2102
  • [8] Non-metastatic castration-resistant prostate cancer: management recommendations
    Alcaraz Asensio, A.
    Alvarez Ossorio, J. L.
    Cozar Olmo, J. M.
    Chantada Abal, V
    Juarez Soto, A.
    Espinos, E. Linares
    Moreno Jimenez, J.
    Munoz Rodriguez, J.
    Perez Fentes, D.
    Plata Bello, A.
    Rodrigo Aliaga, M.
    Unda Urzaiz, M.
    Vilaseca, A.
    ACTAS UROLOGICAS ESPANOLAS, 2022, 46 (04): : 193 - 213
  • [9] Metastatic castration-resistant prostate cancer
    Henriques, Vanessa
    Wenzel, Mike
    Demes, Melanie-Christin
    Koellermann, Jens
    PATHOLOGE, 2021, 42 (04): : 431 - 438
  • [10] Optimal Sequencing of Docetaxel and Abiraterone in Men With Metastatic Castration-Resistant Prostate Cancer
    Maughan, Benjamin L.
    Xhou, Xian C.
    Suzman, Daniel L.
    Nadal, Rosa
    Bassi, Sunakshi
    Schweizer, Michael T.
    Antonarakis, Emmanuel S.
    PROSTATE, 2015, 75 (15): : 1814 - 1820